Fecha de recepción: 03/09/2018 – Fecha de aceptación: 15/10/2018
Medina Guerrero A, García Muñoz S, Bellver Albertos M, García Martínez T, Lorente Fernández L, Soler Company E
Servicio de Farmacia. Hospital Arnau de Vilanova-Lliria. Valencia (España)
Álvaro Medina Guerrero w Hospital Arnau de Vilanova w C/San Clemente 12 w 46015 Valencia (España)
Objectives: To evaluate knowledge that patients have on cancer treatment on the possible involvement in driving produced by medications, as well as the level of appreciation of the risk. To identify the appearance of adverse drugs reactions associated with these drugs and their relationship with the perceived changes in the way of driving. From the results obtained, implement improvements in the information circuits and introduce as a new variable in decision-making the influence on driving.
Material and methods: Prospective, descriptive and transversal study developed in the outpatient pharmaceutical unit and day hospital of our health department, from February to April 2018. The population under study was the patients in treatment with oncologic drugs that influence driving.
Results: We included 107 patients who had a driving license and received treatment with antineoplastic agents. 57.9% were unaware of the existence of the driving pictogram and 48.6% did not know its meaning. 38.3% of patients reported the appearance of adverse reactions that could interfere with driving since they had begun treatment with the drugs under study, and 11.2% had perceived differences in their driving.
Conclusions: The appearance of adverse reactions associated with the studied drugs is directly related to the perception of changes in the way of driving.
The current driving pictogram is not informative enough for patients. Identify these needs, is the starting point to develop new information channels that ensure their correct understanding.
Key Words: Antineoplastic agents, automobile driving, patient-related outcomes, adverse drug reactions.
Download PDF: Influencia de los medicamentos oncológicos en la capacidad de conducción